Abundant Produce reports positive sales developments
Published 29-NOV-2017 12:22 P.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Abundant Produce (ASX:ABT) today reported that Singles Day promotions of Lycopene Active Face Cream have resulted in distributor sales of over A$60,000, as well as more than four million Singles Day visits to the Abundant Natural Health (ANH) listing on the Woolworths Tmall site.
Alongside a more than tenfold increase in social media followers, this exposure translates into significant brand awareness for the company.
“The traffic to Woolworths Tmall site was surprisingly strong for a single SKU [stock keeping unit] that had only been launched 45 days prior on Tmall,” ANH CEO, Shanan Birkin said.
“We are delighted at the interest which demonstrates the brand strength of 100 per cent natural, ethically sourced, Australian made produce, backed by a proud collaboration between two of Australia’s senior research universities.”
December quarter sales also continue to build. Total sales to date exceed A$120,000, which is around a quarter of the company’s initial product run.
“More importantly, our brand presence is growing, paving the way for the new product lines currently in development,” Birkin said.
“Chinese distributors have taken notice and we are currently negotiating expanded distribution partnerships with leading e‐commerce sites. This complements our drive to place product into leading Australian retail chains, the new e-commerce website, and our activities with Australian Diagou groups.”
It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
A brand awareness strategy
Accessing decades of plant breeding expertise in collaboration with Sydney University, ABT is developing unique extracts for a range of natural skin care products that brings together the best of science and nature.
In taking this to a high-impact marketing level, ANH’s new marketing manager Claire Woods is implementing a five‐channel strategy, utilising the following streams: Facebook, Instagram, bloggers/vloggers with mass followings, recognisable endorsers, and software bots to ensure the company’s name comes up again and again.
The key priority for the Australian market in 2017 and through 2018 is to position and grow the ANH brand in the high-end, ‘luxe skincare’ category — ultimately driving sales both here and overseas.
The Australian science space
Recent promotion by the UNSW at its annual Innovation Summit, held this year at the Westin Hotel in Sydney, provided exposure to the company’s strong links to Australian science.
The exhibition showcased 40 cutting‐edge technologies and recognised ANH’s contribution to research, working with eminent scientists from UNSW.
Source: Abundant Produce
More products in the mix
Currently, ABT has one product available for sale, yet this is only the first in a suite of Lycopene face products. New products will target lips and eyes, providing a complete facial treatment range.
Broadening the brand and approaching a wider market, the company is developing a range of magnesium-based products, offering relief for aching muscles and aiding endurance sports recovery.
ANH is also targeting the highly profitable psoriasis and eczema market with an additional skin care range in the pipeline.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
